Clinical Trials · NCT00239629

Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial

CompletedPhase 4Teriparatide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
73
Start date
Sep 2005
Locations
11 sites, 6 countries
Primary endpoint
The primary efficacy measure is the mineralization surface (MS%BS) evaluated in double tetracycline stained bone biopsies.
View Teriparatide compound reference